NCT02467842View on ClinicalTrials.gov

Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

1,503

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

May 31, 2015

Conditions
Influenza
Interventions
BIOLOGICAL

NBP607-QIV

Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria

BIOLOGICAL

NBP607-Y

Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata

BIOLOGICAL

NBP607-V

Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria

All Listed Sponsors
lead

SK Chemicals Co., Ltd.

INDUSTRY

NCT02467842 - Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects | Biotech Hunter | Biotech Hunter